KISS! Keep NDA/BLA submissions manageable. Don’t submit three zillion clinical studies and analyses. Limit the material to what the FDA can realistically review during the PDUFA review period. More info can be submitted later as part of an sNDA/sBLA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.